Affimed (NASDAQ:AFMD) Receives $16.00 Consensus Price Target from Brokerages

Affimed (NASDAQ:AFMD) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $16.00.

AFMD has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Affimed in a report on Friday, November 15th. Stifel Nicolaus decreased their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $2.62 on Friday. The business’s 50 day simple moving average is $3.38 and its 200 day simple moving average is $4.42. Affimed has a 1 year low of $2.61 and a 1 year high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. On average, sell-side analysts anticipate that Affimed will post -4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Affimed

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Choreo LLC bought a new position in shares of Affimed in the 2nd quarter valued at $54,000. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares in the last quarter. Jane Street Group LLC bought a new stake in Affimed during the 3rd quarter worth $44,000. Finally, Point72 Asset Management L.P. increased its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares in the last quarter. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.